Orion Pharma's ODM-212 Receives FDA Orphan Drug Designation for Mesothelioma Treatment
核心洞察
Orion Pharma's investigational drug ODM-212 has received Orphan Drug Designation from the US FDA for treating mesothelioma, a rare and difficult-to-treat cancer affecting fewer than 200,000 people in the US.
ODM-212 is an oral small-molecule pan-TEAD inhibitor currently being tested in a Phase 2 clinical study called TEADES for patients with malignant pleural mesothelioma and other solid tumors with Hippo pathway dysfunction.
The orphan drug designation qualifies Orion Pharma for regulatory incentives including tax credits, exemption from user fees, and eligibility for seven years of market exclusivity following approval.
Orion CorporationSearch company announced that its investigational cancer therapy ODM-212Search drug has received Orphan Drug Designation from the US Food and Drug Administration for the treatment of mesotheliomaSearch disease. The FDA grants orphan drug designation to investigational therapies addressing rare diseases or conditions that affect fewer than 200,000 people in the United States.
Novel TEAD Inhibitor Targets Rare Cancer
ODM-212Search drug is an oral small-molecule pan-TEADSearch term (Transcriptional Enhanced Associate Domain) inhibitor currently being evaluated in a Phase 2 clinical study called TEADES. The trial is investigating the drug's efficacy in treating malignant pleural mesotheliomaSearch disease, epithelioid hemangioendotheliomaSearch disease, and other solid tumors with dysfunction in the Hippo pathwaySearch term.
The global trial is being conducted at leading oncology centers in the US and Europe, enrolling patients who have progressed after receiving standard treatments and have no further treatment options. The study's primary endpoints focus on safety and tolerability, while secondary endpoints include Overall Response Rate, Progression Free Survival, and Overall Survival.
Mechanism of Action and Therapeutic Rationale
ODM-212Search drug targets the Hippo signaling pathway, which regulates cell growth and organ size. Dysregulation of this pathway, particularly through YAP/TAZSearch term activation, can lead to uncontrolled tumor growth and resistance to cancer therapies. The drug works through multiple mechanisms: blocking TEADSearch term transcription factors, disrupting YAP-TEAD protein-protein interactions, and inhibiting TEAD auto-palmitoylation, which is essential for TEAD activity.
"Receiving orphan drug designation for mesotheliomaSearch disease is an important milestone for the ODM-212Search drug program. It underscores the importance of developing urgently needed innovative therapies for patients living with mesothelioma," said Praveen Aanur, MD, MPH, MBA, Chief Medical Officer, Oncology Therapy Area, Orion PharmaSearch company.
Regulatory Benefits and Development Path
The orphan drug designation qualifies Orion PharmaSearch company for several regulatory incentives, including tax credits, exemption from user fees, and eligibility for a seven-year period of market exclusivity following approval. However, the designation does not shorten development time or regulatory review time, nor does it provide any advantage in the regulatory review or approval process.
Orion PharmaSearch company is a globally operating Nordic pharmaceutical company with over a century of experience in drug development. The company focuses its pharmaceutical R&D efforts primarily on oncology and pain management. In 2025, Orion reported net sales of EUR 1,890 million and employs approximately 4,000 professionals worldwide.